COURSE DESCRIPTION:

Join the multidisciplinary experts of Miami Cancer Institute for an interactive, evidence-driven series designed to elevate the care of patients with HER2+ metastatic breast cancer.

As part of this performance and quality improvement initiative, Baptist Health MCI will highlight the latest clinical evidence and best-practice guidelines to strengthen the coordinating the care for breast cancer patients receiving antibody–drug conjugates (ADCs).

Participants will gain practical, actionable strategies to optimize the use of ADCs, improve coordination across care settings, and enhance the early identification and proactive management of ADC-related adverse events. This program equips healthcare providers with the tools needed to deliver safer, effective, and seamless care for patients currently receiving—or being considered for—ADC therapy.

COMMERCIAL SUPPORT:

Baptist Health gratefully acknowledges the educational grants provided by Daiichi Sankyo, Inc., and AstraZeneca.


TARGET AUDIENCE:

Breast Medical Oncologists, Radiation Oncologists, Emergency Medicine Physicians, Infusion Nurses, Nurse Navigators, Advanced Practice Registered Nurses, Pharmacists, Pharmacy Technicians, Physician Assistants/Physician Associates, Pulmonologists, Radiologists, Laboratory Personnel, Schedulers, Medical Assistants, Patient Care Facilitators, and all personnel involved in the care of the breast cancer patient.

LEARNING OBJECTIVES:

• Assess institutional needs and care gaps by analyzing baseline data on current practices in the management of metastatic breast cancer (mBC).
• Evaluate existing institutional procedures to identify opportunities for improvement, aiming to enhance proactive detection and early management of antibody–drug conjugate (ADC)–related adverse events (AEs) and strengthen interprofessional communication and care coordination.
• Determine necessary changes at both human and system levels to address identified practice gaps in the current management of mBC.
• Implement targeted strategies to facilitate earlier recognition of side effects, particularly interstitial lung disease (ILD), for patients receiving ADCs across multiple hospital departments, including the Emergency Room, Radiology, and Infusion Center.
   

FACULTY

Manmeet Ahluwalia, M.D., MBA, FASCO
Chief of Medical Oncology | Chief Scientific Officer | Deputy Director
Fernandez Family Foundation, Endowed Chair in Cancer Research
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance

Fatma Nihan Akkoc Mustafayev, M.D.
Postdoctoral Research Associate (Neuro-Oncology)
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance

Reshma L. Mahtani, D.O.
Chief of Breast Medical Oncology
Miami Cancer Institute 
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance

Ana Sandoval Leon, M.D.
Medical Oncologist
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance

Diana Van Ostran, Pharm.D., BCOP
Breast Cancer Clinical Pharmacy Specialist
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance

Manmeet Ahluwalia, M.D., faculty for this educational activity, received a grant from Pfizer and Incyte; is a consultant for Bayer, Xoft, Apollomics, Autem therapeutics, GT Medical Technologies, Modifi Biosciences, Bugworks, Allovir, EquilliumBio, VBI Vaccines, Servier Pharmaceuticals, Incyte, Recordati, Novocure; and owns stocks from Mimivax, Trisalus Lifesciences, LiveAI, and RYGHT. 

Fatma Nihan Akkoc Mustafayev, M.D., faculty for this educational activity, has no relevant financial relationships to disclose, and her presentation or discussion will not include off-label or unapproved product usage. 

Reshma Mahtani, D.O., faculty of this educational activity, is a consultant for Agendia, AztraZeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Eli Lilly, Novartis, Pfizer, Puma, and Stemline, and has indicated that the presentation or discussion will include off-label or unapproved product usage.

Ana Sandoval Leon, M.D., faculty for this educational activity, is an advisor for AstraZeneca, Stemline, Gilead, Daiichi, Eli Lilly and Boheringer Ingelheim; her presentation or discussion will include off-label or unapproved product usage. 

Diana Van Ostran, Pharm.D., BCOP, faculty for this educational activity, has no relevant financial relationships to disclose, and her presentation or discussion will not include off-label or unapproved product usage. 

All relevant financial relationships for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose. 

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been approved for a maximum of 8 credit hours, CE Broker Course #20-1346668, by the Florida Boards of Medicine, Osteopathic Medicine and Physician Assistants.

This activity has also been approved for a maximum of 8 credit hours for Nurse Practitioners, Nurses, Laboratory Personnel and Pharmacists and Techs. Baptist Health South Florida CE Broker Provider #50-182.